Bolt Biotherapeutics Prices Upsized Initial Public Offering
About Laura Testa-Reyes
This author has yet to write their bio.
Meanwhile lets just say that we are proud Laura Testa-Reyes contributed a whooping 5 entries.
Bolt Biotherapeutics Expands Board of Directors with Appointment of Kathleen LaPorte
Bolt Biotherapeutics Presents Ongoing Clinical Trial Poster at San Antonio Breast Cancer Symposium 2020 Virtual Meeting
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity Ackerman SE, et al., Nature Cancer (2020)
Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors Presented at: 2020 San Antonio Breast Cancer Symposium